DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Mudaliar S, Henry RR, Sanyal AJ. et al.
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Gastroenterology 2013;
145 (03) 574.e1-582.e1
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.